Akebia Therapeutics Reports Q3 2026 Loss of $14.4 Million, Revenue of $36.9 Million Misses Estimates
Total revenue lands below the $46.94 million analyst estimate; Vafseo patient counts climb roughly 140% year over year while Auryxia sales decline on generic competition Related Stocks: AKBA ,